All my sins are of omission
The kung fu hippie from Gansta City
The regulatory climate at the FDA is changing rapidly. This has nothing to do with the incoming administration, though it seems unlikely that current trends at the FDA are going to reverse.
Investing in human biotech has been risky because the stock lives or dies based on regulatory approval. Recently the FDA seems to have lowered the regulatory bar for drugs aimed at serious progressive diseases which do not have meaningful therapies.
Although biotech investing will remain similar to "putting it all on red," this may be the time to invest in companies with drugs in the pipeline for orphan diseases.
None of this is insider knowledge. Please do your own research, and as always caveat emptor.
What about GM me the insider stuff?